Synthetic lethality
Top View
- Regulation of DNA Damage Response and Homologous Recombination Repair by Microrna in Human Cells Exposed to Ionizing Radiation
- CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
- Drug Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of Dbait and PARP Inhibitors
- RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status
- Synthetic Lethality-Mediated Precision Oncology Via the Tumor Transcriptome
- Synthetic Lethality: Beating Cancer at Its Own Game Jane De Lartigue, Phd
- ATM and ATR As Therapeutic Targets in Cancer
- Breast Cancer Predisposition Genes and Synthetic Lethality
- Exploiting Synthetic Lethal Vulnerabilities for Cancer Therapy
- Compound F779-0434 Causes Synthetic Lethality in BRCA2-Deficient Cancer Cells by Disrupting RAD52– Cite This: RSC Adv.,2018,8, 18859 Ssdna Association†
- CIP2A Is a Prime Synthetic-Lethal Target for BRCA-Mutated Cancers
- Mir-509-3 Augments the Synthetic Lethality of Parpi by Regulating HR
- ATM Loss Leads to Synthetic Lethality in BRCA1 BRCT Mutant Mice Associated with Exacerbated Defects in Homology-Directed Repair
- Epigenetic Synthetic Lethality Approaches in Cancer Therapy Haoshen Yang, Wei Cui* and Lihui Wang*
- ATM Signalling and Cancer
- What's Next After PARP Inhibitors for BRCA Mutated Cancers?
- Synthetic Lethality As an Engine for Cancer Drug Target Discovery
- Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach